Recombinant Streptomyces actuosus Nosiheptide precursor | MyBioSource MBS1116969 product information

product summary

company name :

MyBioSource

product type :

protein

product name :

Recombinant Streptomyces actuosus Nosiheptide precursor

catalog :

MBS1116969

quantity :

0.05 mg (E-Coli)

price :

190 USD

more info or order :

MyBioSource product webpage

product information

catalog number :

MBS1116969

products type :

Recombinant Protein

products full name :

Recombinant Streptomyces actuosus Nosiheptide precursor

products short name :

Nosiheptide precursor

products name syn :

Antibiotic 9671-RP1

other names :

Nosiheptide; Nosiheptide precursor; Antibiotic 9671-RP

products gene name :

nosM

other gene names :

nosM; NOS

uniprot entry name :

NOSM_STRAS

host :

E Coli or Yeast or Baculovirus or Mammalian Cell

sequence positions :

Jan-50

sequence length :

sequence :

MDAAHLSDLDIDALEISEFLDESRLEDSEVVAKVMSASC
TTCECCCSCSS

purity :

Greater than 90% as determined by SDS-PAGE.

form :

Liquid containing glycerol; lyophilization may be available upon request.

storage stability :

Store at -20 degree C, for extended storage, conserve at -20 degree C or -80 degree C.

products description :

Inhibits bacterial protein biosynthesis by binding to ribosomes. Specifically, binds to the complex of 23S rRNA and ribosomal protein L11 (RPLK) in the 50S ribosomal subunit. While allowing a weak binding of elongation factor G (EF-G) to the ribosome and subsequent GTP-hydrolysis, probably impairs conformational changes in both the ribosome and EF-G which are necessary for translocation. In vitro, inhibits Gram-positive bacteria S. aureus strain 209P (MIC=0. 0009 ug/ml), S. aureus strain 133 (MIC=0. 0019 ug/ml), S. aureus strain B3 (MIC=0. 003 ug/ml), S. aureus strain Hb (MIC=0. 003 ug/ml), M. citreus strain ATCC 8411 (MIC=0. 0038 ug/ml), M. lysodeikticus strain ATCC 4698 (MIC=0. 003 ug/ml), S. lutea strain ATCC 9341 (MIC=0. 0011 ug/ml), S. faecalis strain ATCC 9790 (MIC=0. 0007 ug/ml), S. viridans (MIC=0. 0065 ug/ml), S. pyogenes holyticus strain Dig7 (MIC=0. 00028 ug/ml), D. pneumoniae strain Til (MIC=0. 00015 ug/ml), N. catrrhalis (MIC=0. 0017 ug/ml), L. casei strain ATCC 6633 (MIC=0. 003 ug/ml), B. cereus strain ATCC 6630 (MIC=0. 0071 ug/ml) and various isolates of L. monocytogenes. In vitro, inhibits Gram-negative bacterium P. multocida strain A125 (MIC=0. 0024 ug/ml) but not M. smegmatis strain ATCC 6630, S. typhimurium, A. aerogenes strain ATCC 8308, P. vulgaris, K. pneumoniae strain ATCC 10031, S. marcescens strain A476, P. aeruginosa strain Bass or B. bronchiseptica strain CN387. Does not inhibit Gram-negative bacterium E Coli strain ATCC 9637 but does inhibit purified ribosomes from E Coli. In vivo, has no systemic effect in mice infected with staphylococci or streptococci when applied orally or subcutaneously. Has a local effect in mice infected subcutaneously or intraperitoneally with staphylococci when applied immediately afterwards. Is not toxic to mice

products references :

Nosiheptide biosynthesis featuring a unique indole side ring formation on the characteristic thiopeptide framework.Yu Y., Duan L., Zhang Q., Liao R., Ding Y., Pan H., Wendt-Pienkowski E., Tang G., Shen B., Liu W.ACS Chem. Biol. 4:855-864(2009) Nosiheptide biosynthesis featuring a unique indole side ring formation on the characteristic thiopeptide framework.Yu Y., Duan L., Zhang Q., Liao R., Ding Y., Pan H., Wendt-Pienkowski E., Tang G., Shen B., Liu W.ACS Chem. Biol. 4:855-864(2009) Nosiheptide, a sulfur-containing peptide antibiotic isolated from Streptomyces actuosus 40037.Benazet F., Cartier M., Florent J., Godard C., Jung G., Lunel J., Mancy D., Pascal C., Renaut J., Tarridec P., Theilleux J., Tissier R., Dubost M., Ninet L.Experientia 36:414-416(1980) Nosiheptide, a sulfur-containing peptide antibiotic isolated from Streptomyces actuosus 40037.Benazet F., Cartier M., Florent J., Godard C., Jung G., Lunel J., Mancy D., Pascal C., Renaut J., Tarridec P., Theilleux J., Tissier R., Dubost M., Ninet L.Experientia 36:414-416(1980). The mode of action of nosiheptide (multhiomycin) and the mechanism of resistance in the producing organism.Cundliffe E., Thompson J.J. Gen. Microbiol. 126:185-192(1981) The mode of action of nosiheptide (multhiomycin) and the mechanism of resistance in the producing organism.Cundliffe E., Thompson J.J. Gen. Microbiol. 126:185-192(1981) Structural basis for contrasting activities of ribosome binding thiazole antibiotics.Lentzen G., Klinck R., Matassova N., Aboul-ela F., Murchie A.I.Chem. Biol. 10:769-778(2003) Mapping the binding site of thiopeptide antibiotics by proximity-induced covalent capture.Baumann S., Schoof S., Harkal S.D., Arndt H.D.J. Am. Chem. Soc. 130:5664-5666(2008) Molecular determinants of microbial resistance to thiopeptide antibiotics.Baumann S., Schoof S., Bolten M., Haering C., Takagi M., Shin-ya K., Arndt H.D.J. Am. Chem. Soc. 132:6973-6981(2010) Antimicrobial susceptibilities of Listeria monocytogenes isolated in Japan.Okada Y., Okutani A., Suzuki H., Asakura H., Monden S., Nakama A., Maruyama T., Igimi S.J. Vet. Med. Sci. 73:1681-1684(2011) NosA catalyzing carboxyl-terminal amide formation in nosiheptide maturation via an enamine dealkylation on the serine-extended precursor peptide.Yu Y., Guo H., Zhang Q., Duan L., Ding Y., Liao R., Lei C., Shen B., Liu W.J. Am. Chem. Soc. 132:16324-16326(2010)

ncbi gi num :

363805424

ncbi acc num :

C6FX52.1

uniprot acc num :

C6FX52

ncbi mol weight :

32.76kD

size1 :

0.05 mg (E-Coli)

price1 :

190 USD

size2 :

0.05 mg (Yeast)

price2 :

190

size3 :

0.2 mg (E-Coli)

price3 :

460

size4 :

0.2 mg (Yeast)

price4 :

460

size5 :

0.5 mg (Yeast)

price5 :

750

more info or order :

MyBioSource product webpage